Improving salvage regimens prior to autologous stem cell transplantation in relapsed/refractory Hodgkin's lymphoma patients: updates in the novel therapy era.
Newer treatment combinations combined with genetic testing may help doctors spare some lymphoma patients from stem cell transplants while improving survival outcomes.
This Mayo Clinic review synthesizes current evidence supporting BV/PD-1 inhibitor-based salvage as the preferred approach for transplant-eligible R/R Hodgkin lymphoma, with emerging data on response-adapted strategies, ctDNA-guided ASCT omission, and consolidation options. The field is moving toward biologically guided risk stratification to individualize therapy and potentially spare patients unnecessary transplant.
What the study was
- Study design
- Narrative review
- Population
- Relapsed/refractory transplant-eligible classical Hodgkin lymphoma patients
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Expert Review of Hematology
Why it surfaced
Well-positioned review from Mayo Clinic on a clinically active area (R/R Hodgkin lymphoma salvage evolution); adds value as an update on ctDNA-guided therapy and ASCT omission strategies; however, narrative review limits score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.